Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Insulin secretion by transplanted β-cells refers to the ability of donor-derived or stem cell–derived pancreatic beta cells, once transplanted into a recipient (typically a person with diabetes), to sense blood glucose and release insulin in response. This process aims to restore physiological insulin production and glycemic control in individuals whose native beta cells are destroyed or dysfunctional, such as those with type 1 diabetes. The main therapeutic goal is restoration of endogenous-like insulin secretion for improved glycemic control without exogenous insulin injections. Limitations include progressive decline in function, immunogenicity, and the innate immune response.
Glucose sensing → Insulin synthesis/secretion → Blood sugar regulation
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin Secretion by Transplanted β-Cells.